Genitourinary Cancers | Specialty

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Dr. Richards on Urinary Tract Infections Associated With Worse Bladder Cancer Outcomes

May 17th 2015

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Dr. Kutikov on Tumor Pathology in Renal Cell Carcinoma

May 16th 2015

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Siteman Cancer Center Houses Broad Research Program

May 15th 2015

Venetoclax Breakthrough Designation, Zarxio Legal Update, and More

May 15th 2015

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma

April 24th 2015

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Cabozantinib in RCC, Cost of Cancer Care, SGR Repeal, and More

April 17th 2015

Dr. Albiges on Implementing mRCC Findings into Practice

April 16th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

The Challenge: Involving Urologists in Cancer Care

April 13th 2015

Management of elevated PSAs, or the next testing equivalent, and prostate cancer should default to the urology world, just like always.

Dr. Balar on Phase III ASSURE Trial Results

March 31st 2015

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

Novel Therapies Needed for Muscle-Invasive Bladder Cancer

March 27th 2015

Anti-PD-L1 Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Potential Targets in Muscle-Invasive Bladder Cancer

March 27th 2015

Treating Relapsed Muscle-Invasive Bladder Cancer

March 27th 2015